Back to MLU Research

Bladder Cancer Study Decision Tree

Explore Bladder Cancer Studies

Protara Phase III

BCG naïve (or no BCG in last 2yrs or 2 or fewer doses of BCG in the last 2yrs) CIS +/- papillary disease. Patients are randomized to TARA-002 (which is similar to BCG but composed of strep pyogenes) vs intravesical chemo – both given via induction and maintenance. Crossover allowed.

View Study

AUA - High Risk